Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2017 and provided an overview ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2017 financial results on Wednesday, November 8, 2017 before market...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the company has initiated dosing in a Phase 1 study of LX9211, an orally-administered...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the European Commission has approved XERMELO® (telotristat ethyl) 250 mg as a...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conference: Lonnel Coats, President and Chief...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the New England Journal of Medicine (NEJM) published the results of the Phase 3...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive pooled continuous glucose monitoring (CGM) data from the pivotal Phase 3...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from four posters highlighting XERMELO® (telotristat ethyl) will be presented ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conference: Jeffrey L. Wade, J.D., Executive Vice...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that new clinical data for sotagliflozin will be presented at the upcoming European...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2017 and provided an overview of...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that it has exercised its option under its collaboration and license agreement with...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2017 financial results on Tuesday, August 1, 2017 before market opens....
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the Committee for Medicinal Products for Human Use (CHMP), the committee of the...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that XERMELO™ (telotristat ethyl) 250 mg has been included as a recommended treatment...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from its two pivotal sotagliflozin studies, inTandem1 and inTandem2, being...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive top-line results from its Phase 3 inTandem3 study of sotagliflozin, an...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that new clinical data for sotagliflozin will be presented at the upcoming 77th American ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conferences: Jeffrey L. Wade, J.D., Executive Vice ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today additional positive data from the Phase 3 inTandem1 study. It was previously announced...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conference: Jeffrey L. Wade, Executive Vice...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2017 and provided an overview of...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.